GSK plc (LON:GSK) Insider Wendy Becker Acquires 536 Shares of Stock

GSK plc (LON:GSK) insider Wendy Becker acquired 536 shares of the company’s stock in a transaction dated Thursday, March 20th. The shares were acquired at an average price of GBX 1,515 ($19.56) per share, for a total transaction of £8,120.40 ($10,484.70).

GSK Trading Down 0.1 %

Shares of GSK stock opened at GBX 1,509 ($19.48) on Friday. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. GSK plc has a fifty-two week low of GBX 1,282.50 ($16.56) and a fifty-two week high of GBX 1,823.50 ($23.54). The stock has a market capitalization of £61.23 billion, a P/E ratio of 24.38, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a 50 day moving average price of GBX 1,441.42 and a 200 day moving average price of GBX 1,439.

GSK (LON:GSK) last issued its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities research analysts predict that GSK plc will post 175.980975 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on GSK. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank dropped their price target on shares of GSK from GBX 1,820 ($23.50) to GBX 1,600 ($20.66) and set a “buy” rating on the stock in a research report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,805.83 ($23.32).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.